Zijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, Rebecca H Boucher, Aimee Jackson, Rachel S Fletcher, Dorian Forte, Jose-Ezequiel Martin, Sonia Fox, James Roberts, Rachel Glover, Erica Harris, Hanna Bridges, Luigi Grassi, Alba Rodriguez-Meira, Adam J Mead, Steven Knapper, Joanne Ewing, Nauman M Butt, Manish Jain, Sebastian Francis, Fiona J Clark, Jason Coppell, Mary F McMullin, Frances Wadelin, Srinivasan Narayanan, Dragana Milojkovic, Mark W Drummond, Mallika Sekhar, Hesham El Daly, Judy Hirst, Maike Paramor, E Joanna Baxter, Anna L Godfrey, Claire N Harrison, Simón Méndez-Ferrer. “Tamoxifen reduces 1 mitochondrial respiration, oncogenic JAK-STAT signaling and mutant allele burden in a subset of myeloproliferative neoplasms -TAMARIN Phase II study” Nature Communications (2023)14:7725. https://doi.org/10.1038/s41467-023-43175-5
Loke J, Upasani V, Gaskell C, Fox S, Fletcher R, Thomas C, Hopkins L, Kumari A, Tang T, Yafai E, Boucher R, Homer V, Toth A, Chan YLT, Randall K, Rider T, O'Nions J, Drew V, Pillai A, Dungarwalla M, Murray D, Khan A, Wandroo F, Moore S, Krishnamurthy P, Huang YJ, Knapper S, Byrne J, Zhao R, Craddock C, Parry H, Moss P, Stanworth SJ, Lowe DM. Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes. Br J Haematol. 2023 Aug;202(3):498-503. doi: 10.1111/bjh.18894. Epub 2023 Jun 12. PMID: 37303189.
Claire N. Harrison, Jyoti Nangalia, Rebecca Boucher, Aimee Jackson, Christina Yap,Jennifer O’Sullivan, Sonia Fox, Isaak Ailts, Amylou C. Dueck, Holly L. Geyer, Ruben A. Mesa, William G. Dunn, Eugene Nadezhdin, Natalia Curto-Garcia, Anna Green, Bridget Wilkins, Jason Coppell, John Laurie, Mamta Garg, Joanne Ewing, Steven Knapper, Josephine Crowe, Ioannis Koutsavlis, Anna Godfrey, Siamak Arami, Mark Drummond, Jennifer Byrne, Fiona Clark, Carolyn Mead-Harvey, ElizabethJoanna Baxter, Mary Frances McMullin, Adam Mead. “Ruxolitinib versus Best Available Therapy for PV intolerant or resistant to Hydroxycarbamide in a Randomized trial”. Journal of Clinical Oncology 41 (19). 01 May 2023. https://doi.org/10.1200/JCO.22.0193
Dillon R, Maycock S, Jackson A, Fox S, Freeman S, Craddock C, Thomas C, Homer E, Leahy J, Mamwell A, Potter N, Russell N, Wei A, Ommen HB, Hemmaway C, Knapper S, Billingham L. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. BMC Cancer. 2022 Nov 14;22(1):1174. doi: 10.1186/s12885-022-10221-2.
Vasiliki Symeonidou, Marlen Metzner, Batchimeg Usukhbayar, Aimee E. Jackson, Sonia Fox, Charles F. Craddock, Paresh Vyas. “Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy.” eJHaem. 08 July 2022. https://doi.org/10.1002/jha2.527
Justin Loke, Marlen Metzner, Rebecca Boucher, Aimee Jackson, Louise Hopkins, Jiri Pavlu, Eleni Tholouli, Mark Drummond, Andy Peniket, Rebecca Bishop, Sonia Fox, Paresh Vyas, Charles Craddock. (2021) “Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy”. British Journal of Haematology, 2021 September 06. Short report http://doi.org/10.1111/bjh.17823
O’Sullivan, J; Hamblin, A; Yap, C; Fox, S; Boucher, R; Panchal, A; Aliman, S; Dreau, H; Howard, K; Ware, P; Cross, N; McMullin, M; Harrison, C; Mead, A; (2019) “The poor outcome in high molecular risk, hydroxycarbamide resistant/intolerant ET is not ameliorated by ruxolitinib”; Blood. 2019 Dec 5;134(23):2107-2111. https://doi.org/10.1182/blood.2019001861
Thomas A Fox, Gillian A Horne, Charles Craddock, Gordon Cook, Stephen O’Brien, Sonia Fox, Anna Hockaday, Graham Silk, and Peter Hillmen (2019) “Trial re-investment to build better research for better impact”,The Lancet (correspondence). Vol 394 August 24, 2019, p635. https://doi.org/10.1016/S0140-6736(19)31363-7
Appleby, N; Eyre .A, T; Cabes, M; Jackson, A; Boucher, R; Yates, F; Fox, S; Rawston, A; Hillmen, P; Schuh, A: “The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease” BMC Cancer 19, 471 (2019) https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5717-y https://doi.org/10.1186/s12885-019-5717-y
Harrison, CN; Mead, AJ; Panchal, A; Fox, S; Yap, C; Gbandi, E; Houlton, A; Aliman, S; Ewing, J; Wood, M; Chen, F; Coppell, J; Panoskaltsis, N; Knapper, S; Ali, S; Hamblin, A; Scherber, R; Dueck, AC; Cross, NCP; Mesa R; McMullin, MF. (2017). “Ruxolitinib versus Best Available Therapy for ET intolerant or resistant to Hydroxycarbamide in a Randomized trial”. Blood, 130:1889-1897